Europe CAR T cell Therapy Market

Europe CAR T cell Therapy Market Size (2023 to 2028)

The CAR T cell Therapy Market in Europe is estimated to grow at a remarkable CAGR from 2023 to 2028.

Y-O-Y growth in the number of cancer cases, the rising occurrence rate of various cancer such as leukemia, lymphoma, and multiple myeloma are majorly driving the European CAR T cell therapy market during the forecast period. Growing investments made by the government and other private organizations are surging the T-cell therapy market growth. Increasing healthcare expenditure and increasing disposable income are fuelling market growth over the forecasting framework.

The cost associated with the CAR T cell therapy market is so expensive and is restraining the market growth to some extent over the forecast timeframe. Also, CAR T cell therapy can cause side effects post-therapy may also hamper the market growth during the forecast period. Lack of awareness regarding T-cell therapy, particularly in rural areas for the therapy process for cancer, restricts the market growth. Poor reimbursement policies from the governments may hamper the CAR T cell therapy market growth in this region.

This research report on the European CAR T Cell therapy market has been segmented and sub-segmented into the following categories.

By Target Antigen:

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

By Application:

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

By Product: 

• Allogeneic
• Autologous

By Therapies: 

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

By End User: 

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regional Analysis:

CAR T cell therapy in the European region is expected to account for a substantial share in the global market during the forecast period due to factors such as growing awareness related to health disorders and rising support from government organizations.

The UK CAR T cell therapy market is predicted to lead the European market due to growing research and development activities. Government initiatives taken for introducing reimbursement policies in support of the poor people are leveling up the market growth in this region. Moreover, an increasing number of cases in the country, advancements in technology for advanced and reliable treatment for cancer diseases, growing pharmaceutical industries, and a rise in the number of clinical studies drive the CAR T cell market growth of the Europe region.

The CAR T cell therapy market in Germany is expected to have the highest growth in the region. The factors stimulating the growth are development within a short period, rising investments among the research institute fuelling the market growth. Moreover, with a growing number of cancer cases in adults and children, an increasing number of clinical trials also enhance growth. The launch of various CAR T-cell therapies and drugs is expected to drive market growth in the European region.

Countries such as France, Spain, and Italy are likely to have considerable growth in this region during the forecast period.

KEY MARKET PLAYERS:

A few of the prominent companies operating in the European CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.